VALUE OF INDICATORS OF CLINICAL BLOOD ANALYSIS FOR DETERMINING THE DEGREE OF THE FIBROTIC PROCESS IN PATIENTS WITH CHRONIC HEPATITIS C
DOI:
https://doi.org/10.11603/1681-2727.2023.4.14244Keywords:
liver fibrosis, chronic viral hepatitis C, clinical blood analysisAbstract
SUMMARY. Viral hepatitis C (HCV) infection is called a "silent epidemic." Chronic HCV provokes progression to liver fibrosis (FL) and liver cirrhosis (CL) and the development of liver failure. The course of chronic HCV quite often has a long period of "symptomlessness". Therefore, timely detection of asymptomatic forms of HCV, which are aggravated by the development of the fibrotic process of the liver, is one of the urgent problems of world medicine.
The aim – to determine the possibilities of indicators of clinical blood analysis of patients with chronic HCV to predict late stages of the disease (with a significant fibrotic process).
Patients and methods. A randomized single-center prospective case-control study was conducted in accordance with the existing ethical standards in compliance with the principles of the Declaration of Helsinki. 47 people were examined (19 (40.4 %) women and 28 (59.6 %) men with chronic HCV and FL. Median Me and 25.0 % (LQ) and 75.0 % (UQ) quartiles and relative values were calculated for quantitative and qualitative measures, respectively. Determination of indicators of clinical blood analysis was carried out by generally accepted methods: the levels of erythrocytes, hemoglobin, hematocrit, erythrocyte indices (average erythrocyte volume, average hemoglobin content in a single erythrocyte and average concentration of hemoglobin in the erythrocyte mass), platelets, thrombocrit, color index, sedimentation rate of erythrocytes, leukocytes, neutrophils (rod and segmentonuclear), eosinophils, lymphocytes and monocytes.
The results. The obtained data indicate a probable (p=0.025) predominance of MCH levels by 1.08 times at 3–4 stages of FL (32.8 [29.7; 34.2] pg) compared to 0–2 (30.3 [29.5; 31.2] pg). Probable (p=0.012) excess of platelets (by 1.28 times) was found at 0–2 stages of FL (229.0 [185.0; 259.0] G/l) compared to 3–4 stages of FL (178.5 [154 .8; 204.8] G/l).
Conclusions. The obtained results regarding changes in clinical blood analysis indicators of chronic HCV patients depending on the course of liver fibrosis can be used as non-invasive prognostic biomarkers for predicting late stages of chronic HCV disease (with significant fibrosis).
References
Hofstraat, S. H. I., Falla, A. M., Duffell, E. F., Hahné, S. J. M., Amato-Gauci, A. J., Veldhuijzen, I. K., & Tavoschi, L. (2017). Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review. Epidemiology & Infection, 145(14), 2873-2885. DOI: https://doi.org/10.1017/S0950268817001947
World Health Organization. WHO urges countries to invest in eliminating hepatitis (2019). www.who.int. Retrieved from: https://www.who.int/news-room/detail/26-07-2019-who-urges-countries-to-invest-in-eliminating-hepatitis
Ryerson, A. B., Schillie, S., Barker, L. K., Kupronis, B. A., & Wester, C. (2020). Vital signs: newly reported acute and chronic hepatitis C cases―United States, 2009–2018. Morbidity and Mortality Weekly Report, 69(14), 399. DOI: https://doi.org/10.15585/mmwr.mm6914a2
Kim, H. S., Yang, J. D., El‐Serag, H. B., & Kanwal, F. (2019). Awareness of chronic viral hepatitis in the United States: an update from the National Health and Nutrition Examination Survey. Journal of viral hepatitis, 26(5), 596-602. DOI: https://doi.org/10.1111/jvh.13060
D'Ambrosio, R., Pasulo, L., Puoti, M., Vinci, M., Schiavini, M., Lazzaroni, S., ... & NAVIGATORE-Lombardia Study Group. (2019). Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. Journal of hepatology, 70(3), 379-387. DOI: https://doi.org/10.1016/j.jhep.2018.11.011
Centers for Disease Control and Prevention. (2021). CDC WONDER. Multiple Cause of Death 1999-2020. National Center on Health Statistics. https://wonder.cdc.gov/mcd-icd10.html
Chhatwal, J., Chen, Q., & Aggarwal, R. (2018). Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling. Infectious Disease Clinics of North America, 32(2), 461–480. https://doi.org/10.1016/j.idc.2018.02.008 DOI: https://doi.org/10.1016/j.idc.2018.02.008
Martinez, M. A., & Franco, S. (2021). Therapy implications of hepatitis c virus genetic diversity. Viruses, 13(1). https://doi.org/10.3390/v13010041 DOI: https://doi.org/10.3390/v13010041
Jin, C. N., Chen, J. D., & Sheng, J. F. (2018). Vitamin D deficiency in Hepatitis C virus infection: What is old? what is new? European Journal of Gastroenterology and Hepatology, 30(7), 741–746. https://doi.org/10.1097/MEG.0000000000001134 DOI: https://doi.org/10.1097/MEG.0000000000001134
Shirasaki, T., Honda, M., Yamashita, T., Nio, K., Shimakami, T., Shimizu, R., Nakasyo, S., Murai, K., Shirasaki, N., Okada, H., Sakai, Y., Sato, T., Suzuki, T., Yoshioka, K., & Kaneko, S. (2018). The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication. Scientific Reports, 8(1). https://doi.org/10.1038/s41598-018-31421-6 DOI: https://doi.org/10.1038/s41598-018-31421-6
Zeremski, M., DImova, R. B., Pillardy, J., De Jong, Y. P., Jacobson, I. M., & Talal, A. H. (2016). Fibrosis Progression in Patients with Chronic Hepatitis C Virus Infection. Journal of Infectious Diseases, 214(8), 1164–1170. https://doi.org/10.1093/infdis/jiw332 DOI: https://doi.org/10.1093/infdis/jiw332
WHO. (2023). Hepatitis C Fact sheet. WHO Website, July. http://www.who.int/news-room/fact-sheets/detail/hepatitis-c
Ghany, M. G., & Morgan, T. R. (2020). Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology, 71(2), 686–721. https://doi.org/10.1002/hep.31060 DOI: https://doi.org/10.1002/hep.31060
World Health Organization. (2016). Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. Geneva: World Health Organization, June, 56.
Buckley, G. J., & Strom, B. L. (2017). A National Strategy for the Elimination of Hepatitis B and C. A National Strategy for the Elimination of Hepatitis B and C, 1–280. https://doi.org/10.17226/24731 DOI: https://doi.org/10.17226/24731
Garcia M, S.-T. J. (2001). Hepatitis C [Hepatitis C]. Medicus, 1(2), 49–53. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
Blach, S., Zeuzem, S., Manns, M., Altraif, I., Duberg, A. S., Muljono, D. H., Waked, I., Alavian, S. M., Lee, M. H., Negro, F., Abaalkhail, F., Abdou, A., Abdulla, M., Abou Rached, A., Aho, I., Akarca, U., Al Ghazzawi, I., Al Kaabi, S., Al Lawati, F., … Razavi, H. (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. The Lancet Gastroenterology and Hepatology, 2(3), 161–176. https://doi.org/10.1016/S2468-1253(16)30181-9 DOI: https://doi.org/10.1016/S2468-1253(16)30181-9
Yang, D. H., Ho, L. J., & Lai, J. H. (2014). Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders. World Journal of Gastroenterology, 20(11), 2962–2970. https://doi.org/10.3748/wjg.v20.i11.2962 DOI: https://doi.org/10.3748/wjg.v20.i11.2962
Lin, C. S., Chang, C. Sen, Yang, S. S., Yeh, H. Z., & Lin, C. W. (2008). Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma. Internal Medicine, 47(7), 569–575. https://doi.org/10.2169/internalmedicine.47.0595 DOI: https://doi.org/10.2169/internalmedicine.47.0595
Kim, W. R., Lake, J. R., Smith, J. M., Schladt, D. P., Skeans, M. A., Harper, A. M., Wainright, J. L., Snyder, J. J., Israni, A. K., & Kasiske, B. L. (2018). OPTN/SRTR 2016 Annual Data Report: Liver. American Journal of Transplantation, 18, 172–253. https://doi.org/10.1111/ajt.14559 DOI: https://doi.org/10.1111/ajt.14559
WHO. (2018). Centre for Disease Analysis. Web Annex B. WHO estimates of the prevalence and incidence of hepatitis C virus infection by World Health Organization region, 2015. Global Hepatitis Report 2017. http://apps.who.int/bookorders.
Lazarus, J. V., Safreed-Harmon, K., Colombo, M., Reic, T., Schatz, E., & Van Damme, P. (2017). Many European countries “flying blind” in their efforts to eliminate viral hepatitis. Nature Reviews Gastroenterology and Hepatology, 14(8), 445–446. https://doi.org/10.1038/nrgastro.2017.98 DOI: https://doi.org/10.1038/nrgastro.2017.98
Abdel-Razik, A., Mousa, N., Besheer, T. A., Eissa, M., Elhelaly, R., Arafa, M., El-Wakeel, N., & Eldars, W. (2015). Neutrophil to lymphocyte ratio as a reliable marker to predict insulin resistance and fibrosis stage in chronic hepatitis C virus infection. Acta Gastro-Enterologica Belgica, 78(4), 386–392. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L607579027
Karagöz, E., Tanoǧlu, A., Ülçay, A., Erdem, H., Turhan, V., Kara, M., & Yazgan, Y. (2016). Mean platelet volume and red cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in patients with chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 28(7), 745–748. https://doi.org/10.1097/MEG.0000000000000647 DOI: https://doi.org/10.1097/MEG.0000000000000647
Catanzaro, R., Sciuto, M., Lanzafame, C., Balakrishnan, B., & Marotta, F. (2020). Platelet to lymphocyte ratio as a predictive biomarker of liver fibrosis (on elastography) in patients with hepatitis C virus (HCV)-related liver disease. Indian Journal of Gastroenterology, 39(3), 253–260. https://doi.org/10.1007/s12664-020-01038-7 DOI: https://doi.org/10.1007/s12664-020-01038-7
Taefi, A., Huang, C. C., Kolli, K., Ebrahimi, S., & Patel, M. (2015). Red cell distribution width to platelet ratio, a useful indicator of liver fibrosis in chronic hepatitis patients. Hepatology International, 9(3), 454–460. https://doi.org/10.1007/s12072-015-9638-9 DOI: https://doi.org/10.1007/s12072-015-9638-9
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 А. Г. Шейко
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration
Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes
This journal is available through Creative Commons (CC) License BY-NC "Attribution-NonCommercial" 4.0
